Design proteins, Is AI better than humans?

The function of proteins is programmed and determined by the genetic information of organisms, which have evolved in nature. However, the characteristics formed during natural selection and evolution sometimes do not meet the strict standards and conditions required in industrial production or medical applications. For example, insufficient protein stability in extreme industrial environments, or direct…

Read More

Overview of DNA synthesis technology

April 25th is DNA day, a big day in the history of biology, because 68 years ago, on April 25th, 1953, James Watson, Francis Crick, and their colleagues published a paper on the double helix structure of DNA in Nature. Since then, the mystery of DNA structure that has plagued generations has been solved, and…

Read More

How does a plasmid exist?

Plasmid DNA is a small double stranded circular DNA molecule that is exposed (without protein binding), structurally simple, independent of bacterial nucleoid DNA, and has the ability to self replicate. Image plasmids usually carry only a small number of genes, especially those related to antibiotic resistance; In addition, plasmids can be transmitted between different bacterial…

Read More
CRISPR-CAS system

CRISPRme, an off target prediction tool that can consider the impact of genetic variation

In recent years, CRISPR gene editing technology has attracted great attention due to its enormous potential in the treatment of hereditary diseases. However, the potential off target effects that may occur during gene editing have always been an important safety concern. In addition, different populations have different genetic information, which poses great difficulties in accurately…

Read More

Frontier | FDA approved new gene editing therapies for the treatment of OTC deficiency in clinical practice; LSTA1, a new drug for the treatment of osteosarcoma, has been recognized as an orphan drug

01 FDA approved new gene editing therapy for the treatment of OTC deficiency in clinical practice On April 4, 2024, the FDA approved the clinical study approval application for ECUR-506 for the treatment of neonatal patients with ornithine aminotransferase (OTC) deficiency. OTC deficiency, also known as hyperammonemia type II, is an X-linked genetic disease caused…

Read More